Generate Biomedicines Inc.

Address: 101 South Street Suite 900

Sponsor Overview

assignment

Specializations

Respiratory Disease Research

Generate Biomedicines Inc. focuses on clinical studies in chronic obstructive pulmonary disease and asthma, with work spanning both mild to moderate asthma and severe uncontrolled asthma. Its research activity is centered on respiratory conditions where persistent airway inflammation and symptom burden remain clinically important.

Chronic Obstructive Pulmonary Disease
Mild to Moderate Asthma
Severe Uncontrolled Asthma

The sponsor’s respiratory portfolio includes studies across multiple countries and collaborating sites, reflecting an active interest in treatment options for chronic airway disease.

Asthma Exacerbation Prevention

Clinical research includes investigation of adjunctive therapy for reducing clinically significant asthma exacerbations in adults and adolescents with severe uncontrolled disease. This indicates a therapeutic emphasis on controlling flare frequency and improving disease stability in difficult-to-manage asthma.

Adjunctive Asthma Therapy
Exacerbation Reduction
Severe Asthma Management

The sponsor is active in therapies intended to address persistent symptoms and acute worsening in patients whose asthma remains inadequately controlled.

Inflammatory Airway Conditions

Generate Biomedicines is also engaged in research relevant to chronic inflammatory airway disorders, including conditions marked by airflow limitation and ongoing respiratory impairment. Its clinical interests cover both long-term symptom control and broader airway disease management.

Airway Inflammation
Airflow Limitation
Chronic Respiratory Impairment

These studies place the sponsor within the field of pulmonary medicine, with a focus on disorders that require sustained therapeutic intervention.

Trial Name	Country	Status
Phase 1 Evaluation of GB-0895 Safety and Tolerability in Patients with Mild to Moderate Asthma and Single Dose in Chronic Obstructive Pulmonary Disease	Germany	Recruiting
Phase 3 Randomized Double‑Blind Placebo‑Controlled Trial of Subcutaneous GB‑0895 as Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma	Belgium Estonia France Ireland Italy Slovakia Spain	Not Yet Recruiting
Phase 3 Study of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma	Bulgaria Croatia Czechia Germany Greece Hungary Latvia Portugal Romania The Netherlands	Recruiting